APA 6th Edition Novak, S. (2014). LIJEČENJE LUPUSNOG NEFRITISA. Liječnički vjesnik, 136 (7-8), 0-0. Preuzeto s https://hrcak.srce.hr/172619
MLA 8th Edition Novak, Srđan. "LIJEČENJE LUPUSNOG NEFRITISA." Liječnički vjesnik, vol. 136, br. 7-8, 2014, str. 0-0. https://hrcak.srce.hr/172619. Citirano 23.01.2020.
Chicago 17th Edition Novak, Srđan. "LIJEČENJE LUPUSNOG NEFRITISA." Liječnički vjesnik 136, br. 7-8 (2014): 0-0. https://hrcak.srce.hr/172619
Harvard Novak, S. (2014). 'LIJEČENJE LUPUSNOG NEFRITISA', Liječnički vjesnik, 136(7-8), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172619 (Datum pristupa: 23.01.2020.)
Vancouver Novak S. LIJEČENJE LUPUSNOG NEFRITISA. Liječnički vjesnik [Internet]. 2014 [pristupljeno 23.01.2020.];136(7-8):0-0. Dostupno na: https://hrcak.srce.hr/172619
IEEE S. Novak, "LIJEČENJE LUPUSNOG NEFRITISA", Liječnički vjesnik, vol.136, br. 7-8, str. 0-0, 2014. [Online]. Dostupno na: https://hrcak.srce.hr/172619. [Citirano: 23.01.2020.]
Sažetak Approximately 50% of patients with systemic lupus erythematosus will develop lupus nephritis. Signs of renal involvement such as proteinuria ³0.5 g/24 h especially with glomerular hematuria and/or cellular casts should be an indication for biopsy. Goals of immunosuppressive treatment in lupus nephritis is remission with avoidance of treatment-related harms. Initial treatment for patients with class III (±V) and class IV (±V) LN are intravenous cyclophosphamide (total dose 3 g over 3 months) or mycophenolate mofetil (or mycophenolic acid) in target dose of 3 g/day for 6 months, always in combination with glucocorticoids, wihile in class V, mycophenolate mofetil in combination with glucocorticoids is recommended. In patients improving after initial treatment, mycophenolate mofetil at lower doses (2 g/day) or azatioprine (2 mg/kg/day), both in combination with low dose prednisone for at least 3 years are recommended. In resistant and relapse cases switch from cyclophosphamide to mycophenolate mofetil, or vice versa, or rituximab is recommended.